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Abstract
Background: Most health authorities do not recommend screening for prostate cancer with PSA tests in
asymptomatic patients who are not at increased risk. However, opportunistic screening for prostate cancer is still
wanted by many patients and it is widely used in primary care clinics, with potential for overdiagnosis and
overtreatment. Better tools for risk assessment have been called for, to better target such opportunistic screening. Our
aim was to explore perceptions about prostate cancer risk and subsequent opportunistic screening among patients
who were not at increased risk of prostate cancer after a first PSA test plus a genetic lifetime risk assessment.
Methods: We undertook semi-structured patient interviews with recording and verbatim transcription of interviews.
Data were analysed thematically.
Results: Three themes were identified: uncertainty of the nature of prostate cancer; perceived benefits of testing; and
conflicting public health recommendations. Prostate cancer was spoken of as an inescapable risk in older age. The
aphorism “you die with it, not from it” was prominent in the interviews but patients focused on the benefits of testing
now rather than the future risks associated with treatment relating to potential overdiagnosis. Many expressed
frustration with perceived mixed messages about early detection of cancer, in which on one side men feel that they
are encouraged to seek medical testing to act responsibly regarding the most common cancer disease in men, and on
the other side they are asked to refrain from opportunistic testing for prostate cancer. Taken together, personal risks of
prostate cancer were perceived as high in spite of a normal PSA test and a genetic lifetime risk assessment showing no
increased risk.
Conclusion: Patients saw prostate cancer risk as high and increasing with age. They focused on the perceived benefit
of early detection using PSA testing. It was also commonly acknowledged that most cases are indolent causing no
symptoms and not shortening life expectancy. There was a frustration with mixed messages about the benefit of early
detection and risk of overdiagnosis. These men’s genetic lifetime risk assessment showing no increased risk did not
appear to influence current intentions to get PSA testing in the future.
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Background
Cancer has been established in public health discourses
as one of the most dreaded diseases in modern society [1].
Strong cultural metaphors include ‘rot that eats you up’
and ‘war between good and bad cells in the body’ [2, 3].
Cancer patient associations in Denmark are well sup-
ported by the public, are highly visible in the media, and
early detection of cancer has caught the attention of both
politicians and citizens [4, 5].
Prostate cancer (PCa) is the most commonly diag-
nosed cancer in men and the second leading cause of
cancer deaths in men in the Western world [6]. Known
risk factors are old age, family disposition, and black eth-
nicity [7]. Approximately 40–50% of all 50-year-old men
and more than 80% of 80-year-old men carry an undiag-
nosed PCa which does not cause premature death [8].
Although PCa is one of the most heritable of all can-
cers, the aetiology of the disease is still poorly under-
stood [9, 10]. The benefit of treatment is limited as PCa
is indolent and non-aggressive in up to 90% of cases
and treatment is often associated with side-effects such
as incontinence and erectile dysfunction [11]. The
Prostate Specific Antigen (PSA) test is still the best
biomarker for detection of PCa but the test has poor
specificity [12, 13]. A high level of PSA may indicate
PCa but PSA levels also increase with age due to benign
prostatic hyperplasia [14]. Opportunistic PSA testing –
defined as medical testing or screening that makes use
of an opportunity engendered by other presentations
and/or tests to which a patient is accustomed or has
already given consent – is common [15]. The risk of
overdiagnosis, defined as disease that ultimately will
not cause individuals to experience symptoms or early
death, has been estimated at 60% or more of all cases
of PCa [16]. The benefit of early detection is considered
to outweigh the risk of overtreatment only in patients
with a family history of PCa [17, 18]. In the context of
poor general knowledge among lay people about the
pitfalls of PSA testing, the PSA test is still widely re-
quested by patients [19–21].
Several initiatives have been made to raise awareness
about the benefits and harms of PSA testing in patients
who are not at increased risk of PCa, including the de-
velopment of decision aids to support the dialogue be-
tween doctor and patient [22–24]. Decision aids have
demonstrated effects on patient knowledge and satisfac-
tion with decisions, but effects on intention to request
PSA testing or actual PSA testing behaviour are more
equivocal [25, 26]. Interventions using genetic lifetime
risk assessment for PCa as a complementary tool to sup-
port active decisions about PSA testing have been devel-
oped and the technology is evolving rapidly [27–30].
However, genetic lifetime risk assessment of PCa still
awaits implementation in general practice [31].
The aim of this study was to explore perceptions about
PCa risk and subsequent opportunistic screening among
patients who were not at increased risk of PCa after a




This was a qualitative study with patients from general
practice in Denmark. It was embedded in an inter-
national translational study (the Molpros Study) about
molecular prediction of PCa risk and aggressiveness, in
which a clinical tool for genetic lifetime risk assessment
of PCa was developed and tested in general practice (the
ProCaRis Study) [32, 33].
Participants and recruitment
In a three-month pilot trial period, five local general
practices were given access to a clinical tool for genetic
lifetime risk assessment of being diagnosed with PCa.
The general practices offered a genetic lifetime risk as-
sessment to any patients requesting a PSA test if they
had no previous or current PCa diagnosis and no previ-
ously measured abnormal PSA-values (> 4.0 mmol/L).
Depending on the result of the PSA test and the risk as-
sessment, three types of reply were provided from the
research laboratory in the Molpros Study to the general
practices: 1) “According to a genetic lifetime risk assess-
ment, this patient has a high genetic lifetime risk of be-
ing diagnosed with prostate cancer. The patient may
benefit from regular individual screening with PSA
tests”, 2) “According to a genetic lifetime risk assess-
ment, this patient has an average lifetime risk of being
diagnosed with prostate cancer. The patient is unlikely
to benefit from regular PSA tests unless he gets symp-
toms associated with prostate cancer”, and 3) “The gen-
etic risk assessment could not determine the genetic
lifetime risk of this patient. The patient may benefit from
regular individual screening with PSA tests”. The GPs
conveyed the result to patients according to usual prac-
tice for giving test results.
We focused here on the second group as this would
be expected to be the largest group in which changes in
PSA testing might lead to more ‘appropriate’ (and less)
testing if genetic risk assessment were to affect such
subsequent behaviours [33]. According to laboratory
data, twelve patients had a normal PSA test result and
an average genetic lifetime risk of being diagnosed with
PCa. The general practices obtained consent from these
patients to disclose their telephone number to the re-
searcher (PK) who contacted them within 4 weeks to in-
vite them to participate in an interview study. All invited
patients received written material about the study before
the interview.
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Data analysis
We developed a semi-structured interview guide for the
interviews, which took place at the patients’ homes [34].
The guide included the following topics: reason for visit-
ing the doctor when the first PSA test had been taken,
symptoms, knowledge about PCa, PSA testing and gen-
etic risk assessment, attitude to PSA screening, inten-
tions to get future PSA tests, risk perception, and
experiences with the healthcare system. An additional
file shows the semi-structured interview guide
[Additional file 1, Interview guide]. Each interview was
conducted by PK or TLON who are experienced re-
search interviewers. Each interview lasted between 45
and 60 min. The interviews were recorded and tran-
scribed verbatim by PK and TLON. Analysis was under-
taken in an inductive thematic manner in which all
datasets were read and re-read in search for emerging
themes (‘funnelling’) [35], using Nvivo 9 software, and
emerging themes were discussed regularly among PK,
FB and AE. The codes were arranged into patterns
which were condensed into themes and discussed
among all authors in order to challenge the analytical in-
sights, and this iterative process continued until consen-
sus was reached and a coherent analysis was developed.
Research ethics
The study followed the Statements on Ethics of the
American Anthropological Association [36] and was ap-
proved by the Danish National Committee on Health
Research Ethics (journal no. 1–10–72-43-12). The study
was approved by the Danish Data Protection Agency
(journal no. 2011–41–6904) and collection of data han-
dled according to their guidelines. The names that ap-
pear in the paper are pseudonyms.
Results
All 12 patients with normal PSA and average lifetime
risk of being diagnosed with PCa accepted to participate
in the interview study (Additional file 2, Table S1). In
the analysis, we identified and explored three themes in
the accounts: uncertainty of the ‘true nature’ of PCa, the
perceived benefits of testing, and frustration about pub-
lic health recommendations.
“It’s Tricky. Some Get It and Live With It”: Uncertainty of
the ‘true’ nature of prostate cancer
A common aphorism about PCa is that “you die with it,
not from it”. This implies that the risk of having (an in-
dolent) PCa is high, but the risk of dying from (an ag-
gressive) PCa is low. The patients in our study also
referred to PCa as “tricky” because the level of aggres-
siveness tends to vary from one case to another. This
was explained by Johan, aged 61: “It’s tricky. Some get it
and live with it. They have a harmless version of it, and
they don’t even know it. Others get a severe diagnosis,
and then they just die. They wither away. It goes into
the bones and makes them crack.” His father was diag-
nosed with PCa after a fall that broke his back. The
course of his disease was short and “ugly” as Johan put
it. His father subsequently died of PCa.
Another patient, Jens, aged 55, also referred to the
unpredictable nature of PCa and mentioned a popular
Danish politician, Svend Auken, who was diagnosed with
PCa in 2004: “You know, you die with it, not from it.
But there are cases where you die quickly. Svend Auken,
for instance. That’s brutal.” Other patients also men-
tioned the Danish TV and cinema documentary ‘Svend’,
which was released in 2011. The film was originally
intended to portray Svend Auken’s political endeavours,
but it also became a portrait of his fight with PCa that
eventually ended his life at the age of 66 in 2009.
Some patients particularly stressed time as a key factor
in defining PCa as a deadly disease or as a chronic con-
dition. Old age is a time of competing health risks, as
expressed in a humorous tone of voice by Johannes,
aged 62: “I don’t give it much thought. You get it or you
don’t. You get really sick or you live with it and die of
something else. Old age is a killer!”.
The interviewed patients referred to PCa as an expected
disease in older age. The youngest patient, Peter, 34 years
old, requested the PSA test because his father got PCa in
his fifties and died from it a few years ago. “If PCa strikes
when the patient is young, the cancer is more severe”,
Peter said. He said about the PSA test and his doctor: “I
guess I get the test to be on the safe side, especially if the
doctor thinks that it is a good idea. And I was really wor-
ried, so he thought it was a good idea.” Peter expected to
worry even more as he grew older, particularly when
reaching the age at which his father had died.
“I’m Not the Type to Say ‘No Thanks’ ”: The perceived
benefits of testing
Most interviewed patients reported that they perceived
early diagnosis before getting symptoms as better than
diagnosis “in due course” as one patient put it. During
the interview, the patients were asked to choose between
a hypothetical early diagnosis of a non-severe PCa that
would not cause early death, or ‘blissful ignorance’ about
it; most patients expressed that they would want to
know. One patient, Regnar, aged 58, exclaimed: “How do
you mean? Of course everybody wants to know! I would
want to know about it! Then they could keep an eye on
me. Even though I couldn’t do anything about it, I’d still
like to know what is going on.” Gunnar, aged 67, said:
“It is always better to know. If you know, you can do
something. If you don’t know, then nothing. My doctor
says’ you don’t die from it, you live with it’. But still, I
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want the PSA test so something can be done before it’s
too late”.
Frede, aged 60, questioned the imperative of early
diagnosis. “You don’t have to know all about all the
faults and flaws. It will just make you sick if you go
around and worry about things that might not happen
anyway. Everybody has cancer in some form, they say.
Body cells mutate and get flawed. Feel good and be in
good shape, that’s the most important thing. Stay men-
tally healthy. But if my doctor advises me to get the PSA
test, I’m not the type to say’ no thanks’. He knows what
he is doing and he knows me”.
No patients showed any particular interest or know-
ledge about genetic lifetime risk assessment (despite all
having had one). When asked about the consequences
for him of a ‘normal/average genetic lifetime risk’ and
his intention to get a PSA test, Peter, aged 34, said:
“They know so much, and they come up with something
new all the time. I don’t know how much I can trust it,
but the more you get tested, the more the doctor knows
about your health, right?” Johannes, aged 62, put it this
way: “Things change. Well, I might as well get the PSA
test again if I’m in the consultation anyway. It feels good
to go with the flow. It’s just a risk assessment, right, not
an insurance policy. You do what you can do. And this
is what you can do”.
“It’s Not Easy to Satisfy Everyone”: public health
recommendations
Frustration about conflicting public health recommenda-
tions and perceived mixed messages was frequently
expressed in the interviews. Harald, aged 55, reasoned:
“We men are told again and again to see a doctor more
often because men live harder and die earlier. It’s not
easy to satisfy everyone. When you go to the doctor, he
argues that the PSA test is used too frequently, and there
are side effects. It’s not rational, is it?”.
John, aged 61, also pointed out a “reprimanding” tone
in public health recommendations to men about taking
care of their health, which was contested when they fi-
nally consulted their doctor: “Sometimes we are accused
of not taking care of ourselves. But listen, I have never
had a day off sick. My health is excellent. I go to check-
ups due to high cholesterol and erysipelas, a skin infec-
tion. But I couldn’t get a PSA test because the doctor
said it was unnecessary. Now my father, he is 86, and
got prostate cancer. I think she [the doctor] should have
listened to me”.
Regnar, aged 58, complained about his doctor: “She is
not easy to convince about the prostate test [PSA test].
She says that it will become too high eventually, when I
get old enough, so if I get the test repeatedly, they will
just find a cancer sooner or later. I can’t see the logic in
what she’s saying. Finding it early is better. So I request
it once a year. And I get it”.
Perceptions about cancer and early diagnosis were
sometimes explained as a result of prominent public
cancer awareness campaigns and personal or celebrity
stories about cancer in the media. Jørgen, aged 59,
recalled the international “Movember” campaign and a
national health campaign by the Danish Cancer Society
about men’s health care-seeking behavior: “The one with
the moustache and the one with ‘Real men visit their
doctor’. You better go! You see health recommendations
targeting men everywhere. We drink and smoke too
much, drive too fast on the highway, exercise too little.
We should have our health checked”.
The cancer story of Svend Auken mentioned above
was also highlighted as a driver of public interest about
cancer. Frede, aged 60, said: “It’s a Svend Auken effect, if
you may call it so. You see it every time a famous person
gets a severe disease – now everybody’s afraid of pros-
tate cancer.”
Some patients discussed possible male discrimination
in cancer research and screening. Jens, aged 55, said (in
a humorous tone of voice): “My wife is right when she
points out that women are invited for screening, but
men are not. Isn’t it about time they invite us?” John,
aged 61, also pointed out that women get screened, but
men do not: “So when you hear that women are offered
screening for cancer, you start wondering why men are
denied screening for cancer ─ especially when you
know for a fact that cancer is so common”.
Discussion
Patients in our study spoke of PCa as a “natural” part of
getting older, and the aphorism “you die with it, not
from it” was often mentioned in the interviews. These
patients spoke of the PSA test as a crucial prerequisite
for cancer detection and they focused on the perceived
benefits of testing now rather than the risks associated
with treatment in the future. Frustration about conflict-
ing public health recommendations was frequently
expressed because public health recommendations for
men to take care of their health (by undergoing various
tests) were contested in the clinic when the patients fi-
nally consulted their doctor, some of whom reportedly
advised them not to take a PSA test. During the inter-
views, the patients did not take into account the normal/
average result of their genetic lifetime risk assessment
when reasoning about future PSA testing for themselves
or for other men.
Limitations
The general practitioners and practice nurses were care-
fully instructed to inform the patients about the risk and
benefits about PSA testing and genetic risk assessment
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but how information was given and results communi-
cated remain unknown. The patients were not con-
cerned about the risks of overtreatment and focused
instead on the perceived benefits of early detection of
PCa. This is surprising given the purpose of a genetic
lifetime risk assessment which is to reduce risk of over-
treatment and side-effects associated with treatment. It
suggests that information in the consultation about the
benefits and risks of PSA testing, and the benefits and
risks of genetic lifetime risk assessment were mixed to-
gether, and it underscores the complexities in general
practice regarding communication about risk of future
disease. Second, there was a time restriction on the re-
cruitment phase because the testing of the clinical tool
in the five general practices followed a protocol involv-
ing a wide range of stakeholders in the translational
study, inside which the interview study was nested [32].
It limited the number of eligible patients for the inter-
view study, constraining opportunity to test or reach sat-
uration or ‘information power’ [37]. We responded to
this by refining the research question during the analyt-
ical process, based on the empirical data, so that conclu-
sions about individuals (male patients) from a specified
group (requesting PSA testing) sharing similar experi-
ences not previously described (normal PSA value in
combination with a genetic lifetime risk assessment
showing average risk of being diagnosed with PCa) could
be drawn [35].
Third, the overall methodological approach to testing
the clinical tool in the ProCaRis Study was to mimic the
way in which clinical tools are implemented in everyday
clinical practice where the success of a new non-
diagnostic clinical tools also depends on convenience
and ability to ‘fit’ with existing procedures. Hence the
general practices were not asked to make any further re-
cords about invited patients who declined to receive a
genetic lifetime risk assessment or potential participants
who were not invited due to time pressure, omission,
etc. Thus we were not able to assess potential selection
bias in the general practices’ recruitment of patients.
However, the strength of our study was that it reflects
how new tests and laboratory analyses are introduced in
general practices because we only “minimally disrupted”
the general practices in their interaction with patients.
Comparison with existing literature
We found that PCa was framed as a ‘natural’ part of be-
coming old, a ‘risk of age’ and blurring the lines between
ageing as a natural process of ‘biomorphism’, and path-
ology [38]. Estimates of individual PCa risk and diagnos-
tic means to detect a PCa were welcomed even though
the uncertainty of PCa was not replaced by certainty
when using the PSA test or the genetic risk assessment.
This is consistent with research showing that the
diagnostic uncertainty of the PSA test may be acknowl-
edged among patients as a ‘maybe test’ and the decision
to undertake PSA testing can be fraught with uncer-
tainty both before and after testing, even if the test result
turns out to be normal [39–41]. In our study, the diag-
nostic uncertainty was also acknowledged as a major pit-
fall, but the perceived opportunity to get a ‘look inside’
was often felt to outweigh the risks of getting a diagnosis
of an indolent PCa.
According to the patients, the decision to undergo
PSA testing was patient-centered or even patient-led in
most cases. They felt they had a right to be screened for
cancer implying that the lack of systematic screening for
more cancer types among men is a poor political deci-
sion. This suggests that the political aspect outweighed
apparent health risks. It is supported by studies showing
that sometimes the desire for a PSA test is unaffected by
information from the GP about the pitfalls of PSA test-
ing while in other cases, recommendations from the GP,
family, or friends have a powerful influence on decisions
about PSA testing [20, 42].
Regarding lifetime risk assessment it has been sug-
gested that a seeming lack of interest in information
about possible implications of (genetic) risk assessment
could be seen against a backdrop of trust in health care
professionals [43, 44]. Many patients decide to let their
GP make the decision for them about testing in
preference-sensitive cases. This may be both rational
and beneficial but it can be difficult for the GP to dis-
criminate between patients who make an informed deci-
sion about letting the GP decide, and patients who do
not realise that they have a choice to make [45]. This
challenges the aspiration for informed decision-making
about new health technology and testing opportunities.
Studies about attitudes to genetic risk assessment of
PCa have found low levels of worry and a high interest
in genetic testing [46–48]. In our study, the genetic life-
time risk assessment did not receive any attention, and
the patients did not seem to discriminate between the
prognostic value of the PSA test here and now, and the
lifetime perspective of a risk assessment. This accords
with research showing that blood testing is perceived as
relatively common and harmless by most patients and
the use of blood testing as part of a diagnostic procedure
has become routine in so many clinical encounters that
it is now ‘mundane’ and unquestioned, and that this
over-rides the details of which test may be involved [49].
It is a common perception among most patients that
PSA testing and treatment of PCa are relatively ‘straight-
forward’, similar to measurement of cholesterol and
treatment with risk-reducing medications. A PSA test
might not be just a simple blood test and patients may
not anticipate the ‘commitment’ to treatment in case of
a positive result [41].
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As in other contemporary Western societies, the dom-
inant health discourse in Denmark is characterised by a
moral imperative to optimise health and reduce expos-
ure to health risks [50]. The patients in our study strug-
gled to balance the moral imperative to seek health care
in time and yet also avoid unnecessary tests with the risk
of overdiagnosis. Our findings substantiate the gap be-
tween the current public health discourses about pro-
active healthcare-seeking, and the clinical pitfalls of early
detection of PCa [51]. This gap might hinder attempts
to reduce PSA testing in patients who are not considered
to be at high risk of PCa. Informed decision-making in
the consultation is crucial to ensure that patients under-
stand the implications of opportunistic testing, but more
research is needed to fully understand the gap, and how
best to support discussion and decision-making.
Conclusion
PCa was perceived as a “natural” part of getting older
and the patients saw opportunistic PSA testing as a
means to reduce the risk of PCa. They were aware of the
risk of overdiagnosis but focused on the perceived bene-
fits of testing. The clinical recommendation of no oppor-
tunistic screening conflicted with a societal health
imperative to seek early detection of cancer. The result
of the genetic lifetime risk assessment was considered
‘just another test’ result which did not influence their
current intentions to get PSA testing in the future. The
results are important to take into consideration before
implementing new tools for genetic lifetime risk assess-
ments in general practice.
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